The purpose of this study is to evaluate the safety of SI-6603 in lumbar disc herniation patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
SKK
Encinitas, California, United States
Adverse events
Time frame: 52 weeks
The leg pain
Time frame: At each assessment time point
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.